Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by BioRestorative Therapies, Inc. (BRTX) on September 13, 2023. The company is incorporated in Nevada and trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders approved three key matters at the Annual Meeting:
- Election of Class III Directors: Lance Alstodt and Patrick F. Williams were elected. Significant broker non-votes (1,907,427 shares) were recorded for both nominees.
- Stock Incentive Plan Amendment: Stockholders approved increasing the number of shares authorized under the 2021 Stock Incentive Plan from 2,500,000 to 3,850,000. The vote was 571,623 For, 276,247 Against, and 22,839 Abstentions.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 2,751,541 For, 15,525 Against, and 11,070 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the impact of the increased share authorization (3,850,000 shares) on potential future dilution.
- Review the significant number of broker non-votes (1,907,427) regarding director elections to understand shareholder engagement levels.
- Confirm the details of the 2021 Stock Incentive Plan amendment in the company's proxy statement.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2023.